The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers
Open accessAbstract
BACKGROUND: The CD44 cell adhesion molecule is aberrantly expressed in many breast tumors and has been implicated in the metastatic process as well as in the putative cancer stem cell (CSC) compartment. We aimed to investigate potential associations between alternatively spliced isoforms of CD44 and CSCs as well as to various breast cancer biomarkers and molecular subtypes. METHODS: We used q-RT-PCR and exon-exon spanning assays to analyze the expression of four alternatively spliced CD44 isoforms as well as the total expression of CD44 in 187 breast tumors and 13 cell lines. ALDH1 protein expression was determined by IHC on TMA. RESULTS: Breast cancer cell lines showed a heterogeneous expression pattern of the CD44 isoforms, which shifted considerably when cells were grown as mammospheres. Tumors characterized as positive for the CD44+/CD24- phenotype by immunohistochemistry were associated to all isoforms except the CD44 standard (CD44S) isoform, which lacks all variant exons. Conversely, tumors with strong expression of the CSC marker ALDH1 had elevated expression of CD44S. A high expression of the CD44v2-v10 isoform, which retain all variant exons, was correlated to positive steroid receptor status, low proliferation and luminal A subtype. The CD44v3-v10 isoform showed similar correlations, while high expression of CD44v8-v10 was correlated to positive EGFR, negative/low HER2 status and basal-like subtype. High expression of CD44S was associated with strong HER2 staining and also a subgroup of basal-like tumors. Unsupervised hierarchical cluster analysis of CD44 isoform expression data divided tumors into four main clusters, which showed significant correlations to molecular subtypes and differences in 10-year overall survival. CONCLUSIONS: We demonstrate that individual CD44 isoforms can be associated to different breast cancer subtypes and clinical markers such as HER2, ER and PgR, which suggests involvement of CD44 splice variants in specific oncogenic signaling pathways. Efforts to link CD44 to CSCs and tumor progression should consider the expression of various CD44 isoforms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective
Götte, M., & Yip, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1464 · Cited by 340
Cited by
CD44: A Multifunctional Mediator of Cancer Progression
Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021) · Biomolecules · doi:10.3390/biom11121850 · Cited by 492
Pradella, D., Naro, C., Sette, C., & Ghigna, C. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0579-2 · Cited by 326
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
Thapa, R., & Wilson, G. D. (2016) · Stem Cells International · doi:10.1155/2016/2087204 · Cited by 312
Abdollahzadeh, R., Daraei, A., Mansoori, Y., Sepahvand, M., Amoli, M. M., & Tavakkoly‐Bazzaz, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27941 · Cited by 261
Therapies targeting cancer stem cells: Current trends and future challenges
Dragu, D. L. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1185 · Cited by 257
Metadata
- Authors
- Olsson, E., Honeth, G., Bendahl, P.-O., Saal, L. H., Gruvberger-Saal, S., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Holm, K., Lövgren, K., Fernö, M., Grabau, D., Borg, Å., & Hegardt, C.
- Venue
- BMC Cancer
- Published
- 2011-09-29
- Volume
- 11
- Issue
- 1
- Pages
- 418-418
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2150079828
- Cited by
- 204
- References
- 1
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. https://app.cochat.ai/papers/10.1186/1471-2407-11-418
- The paper
- Olsson, E., Honeth, G., Bendahl, P.-O., Saal, L. H., Gruvberger-Saal, S., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Holm, K., Lövgren, K., Fernö, M., Grabau, D., Borg, Å., & Hegardt, C. (2011). CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. https://doi.org/10.1186/1471-2407-11-418
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.